Cynosure Group LLC Takes $521,000 Position in Amgen Inc. $AMGN

Cynosure Group LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,593 shares of the medical research company’s stock, valued at approximately $521,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares in the last quarter. State Street Corp boosted its holdings in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares in the last quarter. Capital World Investors boosted its holdings in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Capital International Investors boosted its holdings in Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Stock Down 0.8%

Shares of NASDAQ:AMGN opened at $347.84 on Wednesday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market cap of $187.73 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 3.52 and a beta of 0.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The firm has a 50 day simple moving average of $341.02 and a 200 day simple moving average of $345.89.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research reports. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Royal Bank Of Canada raised their target price on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Argus reduced their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Finally, Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.